Presbia Adds Renowned Ophthalmologist Dr. Tamayo to Its Medical Advisory Board

Further Expertise Added As Company Anticipates Additional Commercialization Activities for the Flexivue™ Micro-Lens

AMSTERDAM--()--Presbia, a leading medical device company specializing in a corneal inlay optical micro-lens solution for presbyopia, announced today that renowned ophthalmologist Dr. Gustavo E. Tamayo of Bogotá, Colombia, has agreed to join its Medical Advisory Board. Dr. Tamayo’s extensive experience and leadership in the field of refractive surgery, especially in the treatment of presbyopia, will build upon the collective expertise of the advisory board, which is chaired by Professor Ioannis Pallikaris, M.D., widely regarded as the “father” of LASIK surgery.

“As we continue working toward our goal of bringing a revolutionary solution to the hundreds of millions of people affected by presbyopia, we are excited to add Dr. Tamayo to our distinguished Medical Advisory Board,” said Vladimir Feingold, Chief Technology Officer of Presbia. ”We look forward to working with Dr. Tamayo as we continue to expand the global reach of the Flexivue™ Micro-Lens as the leading solution to this widespread age-related vision problem.”

Dr. Tamayo, Director of the Bogotá Laser Refractive Institute, holds several patents for the treatment of presbyopia, irregular astigmatism and phacoemulsification surgical procedures. In addition, he has authored almost 100 medical journal articles, 11 book chapters and has lectured all over the world at medical universities, hospitals and conferences. He was the first surgeon to perform a Contoured Ablation Patterns (CAP) Method treatment for irregular astigmatism, which has enabled doctors to perform such surgeries more quickly and easily, and he was also the first surgeon to treat a wave-front guided ablation in a human eye.

“Surgical correction will become the most frequent treatment for presbyopia over the next few years, due in large part to the rapidly increasing number of potential patients around the world who are embracing this new solution for the treatment of presbyopia,” Dr. Tamayo said. “The Flexivue™ Micro-Lens implantation will be at the forefront of this movement toward surgical treatments because it is easy to implant, effective and safe. Most importantly, it is a completely reversible or exchangeable surgery that allows the implanted lens to be upgraded if a patient’s presbyopia advances with age and/or the prescription needs to be changed.”

In his distinguished career, Dr. Tamayo has served as a Fellow in anterior segment surgery at the Fundación Oftalmológica Argentina, a Fellow of ocular echography at the University of Iowa Hospitals and Clinics, as well as a Fellow in statistical analysis from University of Waterloo, Canada with a sub-specialty fellowship in corneal transplants at Duke University.

Dr. Tamayo is member of several medical associations, including the American Academy of Ophthalmology, The Cornea Society, and both the American and European Societies of Cataract & Refractive Surgery. He is also a member of the Executive Committee of the International Society of Refractive Surgery and serves on the board of the Italian Refractive Surgery Society, as well as a reviewer of the Journal of Cataract and Refractive Surgery, Journal of Refractive Surgery and Middle East Africa Council of Ophthalmology Journal.

About Presbia’s Flexivue™ Micro-Lens

Presbia’s revolutionary solution to presbyopia involves implanting the FlexivueMicro-Lens in the corneal stroma of one of the patient’s eye. The hydrophilic polymer lens, just 3mm in diameter and approximately 15 microns in edge thickness, is made of similar materials to those that have been used in intraocular lenses for the past 20 years. Using Presbia’s proprietary insertion tool, the lens is placed in a pocket created in the cornea by a femtosecond laser—the same kind of laser routinely used for LASIK surgery.

The pocket then seals itself, holding the lens in place in the center of the visual axis. The lens can stay in place permanently, or can be easily and safely removed if, for example, the patient’s presbyopia advances and a stronger prescription is required. The procedure typically takes less than 10 minutes, is performed on the non-dominant eye, and does not require general anesthesia. Since the Flexivue™ Micro-Lens is implanted utilizing standard femtosecond lasers, the procedure requires no additional capital investment by the surgeon’s practice.

An animated video of the procedure is available at www.presbia.com.

ABOUT PRESBIA

Presbia is a leading ophthalmic-device company focused on the development of solutions for presbyopia, the age-related loss of the ability to read or focus on near objects. Chief among these approaches is the Presbia Flexivue™ Micro-Lens, a 3mm-diameter lens implanted using femtosecond laser technology. Further information is available at www.presbia.com.

Note: The Presbia Flexivue™ Micro-Lens and related medical procedures are not available in the United States and have not been evaluated or approved by the U.S. Food and Drug Administration.

Contacts

Mendel Communications
Sarah Troutt, 212-397-1030
sarah@mendelcommunications.com

Contacts

Mendel Communications
Sarah Troutt, 212-397-1030
sarah@mendelcommunications.com